Hyperhidrosis Treatment Market – By Type (Axillary, Palmar, Plantar), Treatment (Topical, Oral [Anticholinergics], Botulinum Toxin Injections), Age (Below 50, Above 50 Years), End-user (Hospitals, ASCs, Dermatology Clinics), Global Forecast (2024 – 2032)

Hyperhidrosis Treatment Market Size

Hyperhidrosis Treatment Market size in 2023 was valued at USD 671.6 million and is predicted to showcase growth at 5.3% CAGR from 2024 and 2032. One of the primary factors driving the growth of the market is the rising awareness and diagnosis of the condition.
 

Traditionally, hyperhidrosis was underdiagnosed and undertreated due to a lack of awareness among patients and healthcare providers. However, increasing public health campaigns and educational initiatives are now highlighting the impact of excessive sweating on quality of life, leading more individuals to seek medical advice and treatment.
 

Furthermore, significant advancements in medical technology are fueling the growth of the hyperhidrosis treatment market. Innovative treatments, such as microwave thermolysis (e.g., MiraDry), laser therapies, and iontophoresis devices, offer effective and less invasive options for managing hyperhidrosis. Additionally, the development of novel botulinum toxin formulations and delivery systems has improved the efficacy and duration of injectable treatments. These technological advancements provide patients with more choices and better outcomes, thus driving market expansion.
 

Hyperhidrosis is a medical condition characterized by excessive sweating beyond what is necessary for thermoregulation. It can be either localized (affecting specific areas like the palms, soles, underarms, or face) or generalized (affecting the entire body). It can significantly impact the quality of life, leading to social, emotional, and occupational challenges. The choice of treatment depends on the severity of the condition, the areas affected, and the patient's response to initial therapies.
 

Hyperhidrosis Treatment Market Trends

• The rising prevalence of hyperhidrosis is a critical factor contributing to the market's growth. Increased stress levels, changing lifestyles, and higher incidence of associated conditions such as obesity and diabetes are contributing to a higher number of hyperhidrosis cases.
   
• For instance, according to National Institutes of Health (NIH), the worldwide prevalence of hyperhidrosis was reported to be ranging from 0.072% to 38% of population. Thus, as the prevalence of hyperhidrosis continues to grow, the need for effective treatment options rises, thereby expanding the market.
   
• Additionally, minimally invasive procedures like botulinum toxin injections (e.g., Botox) and microwave thermolysis are gaining popularity due to their effectiveness and relatively low risk. Patients increasingly prefer these options over traditional surgical interventions, which can be more invasive and have longer recovery periods. This shift in preference is further bolstering the growth of the market.
   

Hyperhidrosis Treatment Market Analysis

Based on type, the market is classified into axillary hyperhidrosis, palmar hyperhidrosis, plantar hyperhidrosis, and other types. The axillary hyperhidrosis segment dominated the global hyperhidrosis market with 44.8% of market share in 2023.
 

• Axillary hyperhidrosis, or excessive underarm sweating, is one of the most common forms of hyperhidrosis, affecting a significant portion of individuals suffering from this condition.
   
• The high prevalence of axillary hyperhidrosis compared to other forms like palmar (hands) or plantar (feet) hyperhidrosis means there is a larger target population for treatments. This contributes to the larger market share for axillary hyperhidrosis treatments.
   
• Further, the axillary hyperhidrosis segment benefits from a wide range of effective treatment options that are readily available and widely accepted by both patients and healthcare providers. These include topical antiperspirants, botulinum toxin injections (such as Botox), and microwave thermolysis (such as MiraDry). thereby driving the growth of axillary hyperhidrosis segment.
   

Based on treatment, the hyperhidrosis treatment market is segmented into topical treatment, oral medications, botulinum toxin injections, iontophoresis, and surgical treatment. The topical treatment segment accounted for majority of market share and was valued at USD 255.9 million in 2023.
 

• Topical treatments, such as antiperspirants, are readily available over the counter, making them a first-line treatment option for many individuals. Their ease of use allows patients to apply these treatments directly to the affected areas without needing medical supervision, appealing to a broad audience.
   
• Additionally, topical treatments are generally more affordable than other options like botulinum toxin injections or surgical procedures, making them an attractive and accessible choice for a wide range of patients.
   
• Thus, owing to the advantages such as widespread accessibility, convenience, and cost-effectiveness, the topical treatment segment is anticipated to witness lucrative growth over coming years.

Based on age, the hyperhidrosis treatment market is divided into below 50 years and above 50 years. The below 50 years segment held highest market share and is anticipated to grow at 5.2% of CAGR over the analysis period.
 

• The below 50 years age segment holds the highest market share in the market primarily due to the higher prevalence of the condition in this demographic.
   
• Hyperhidrosis often begins in adolescence or early adulthood, leading to a larger affected population among younger individuals.
   
• Further, this age group is more aware about available treatment options and willing to try new therapies to manage their symptoms effectively. These factors collectively drive the growth of this segment in global market.
   

Based on end-user, the hyperhidrosis treatment market is categorized into hospitals, ambulatory surgical centers, dermatology clinics, and other end-users. The hospitals segment accounted for significant market share in 2023 and is expected to reach USD 562 million by 2032.
 

• Hospitals provide access to advanced treatments and technologies necessary for managing hyperhidrosis effectively. Procedures like botulinum toxin injections, microwave thermolysis, laser therapies, and surgical interventions are routinely performed in hospital settings, attracting patients seeking comprehensive and specialized care.
   
• Moreover, hospitals employ a wide range of healthcare professionals, including dermatologists, neurologists, and surgeons, who possess the expertise needed to diagnose and treat hyperhidrosis accurately. This expertise instills confidence in patients, leading to higher utilization of hospital-based treatments.

North America hyperhidrosis treatment market was valued at USD 280.7 million in 2023 and is anticipated to grow with CAGR of 5% to reach USD 437.2 million by 2032.
 

• The region boasts advanced healthcare infrastructure, offering patients access to a wide array of treatment options facilitated by modern facilities and skilled healthcare professionals.
   
• Additionally, technological advancements and ongoing research initiatives further enhance the region's prominence by continually improving treatment modalities.
   
• These factors drive the growth of North America market.
   

The U.S. hyperhidrosis treatment market is predicted to witness growth at 4.9% of CAGR over the coming years.
 

• The high prevalence of hyperhidrosis among the American population, coupled with increased awareness about the condition, has spurred demand for effective treatment options.
   
• For instance, as per an article published in the Journal of Dermatology, the prevalence of hyperhidrosis in the U.S. population was 2.8% to 4.8%. Thus, the high prevalence of hyperhidrosis, coupled with growing awareness of the condition and available treatment options, drives demand for hyperhidrosis treatments in the country.
   

Germany hyperhidrosis treatment market accounted for a significant position in global market.
 

• Germany is a leader in technological advancements and medical research, particularly in the field of dermatology and aesthetic medicine.
   
• The country's pharmaceutical companies, medical device manufacturers, and research institutions are at the forefront of developing innovative therapies, conducting clinical trials, and advancing treatment modalities for hyperhidrosis.
   
• These advancements lead to the introduction of new and improved treatment options, enhancing Germany's attractiveness as a hub for hyperhidrosis treatment innovation and driving its position in global market.
   

China hyperhidrosis treatment market is anticipated to grow significantly during the forecast period.
 

• According to National Institutes of Health, the prevalence of primary hyperhidrosis in China was estimated to around 14.5%. This prevalence indicates a substantial portion of the population experiencing excessive sweating, creating a large potential market for hyperhidrosis treatments.
   
• As more individuals seek relief from the symptoms of hyperhidrosis, there is a corresponding increase in demand for effective treatment options, driving growth in the market.
   

Hyperhidrosis Treatment Market Share

The market is characterized by a competitive landscape with several key players vying for market share. Companies operating in this market are focused on developing innovative treatment modalities, expanding their product portfolios, and strengthening their presence in key regions to gain a competitive edge.
 

Hyperhidrosis Treatment Market Companies

Prominent players operating in the hyperhidrosis treatment industry include:

• AbbVie Inc.
• Avanor Healthcare Ltd.
• Brickell Biotech Inc.
• Dermadry Laboratories Inc.
• Dermavant Sciences Inc.
• Hugel, Inc.
• Eirion Therapeutics, Inc
• Eli Lilly and Company
• Intas Pharmaceuticals Ltd
• Kaken Pharmaceutical Co., Ltd.
• Maruho Co., Ltd.
• miraDry, Inc.
• SweatBlock
   

Hyperhidrosis Treatment Industry News:

• In October 2022, Candesant Biomedical launched the "SweatTech Initiative" to raise awareness about the significant impact of hyperhidrosis, provide information on how treatments have evolved over the decades, and demonstrate the ongoing need for more modern treatments. This highlighted the limitations of current therapies and the potential for Candesant's novel approach.
   
• In May 2022, Maruho Co., Ltd. launched Rapifort wipes 2.5% for the treatment of primary axillary hyperhidrosis in Japan. This product launch helped the company to enhance their product portfolio.
   

The hyperhidrosis treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Axillary hyperhidrosis
• Palmar hyperhidrosis
• Plantar hyperhidrosis
• Other types

Market, By Treatment

• Topical treatment
• Oral medication
  • Anticholinergics
  • Other oral medications 
• Botulinum toxin injections
• Iontophoresis
• Surgical treatment

Market, By Age

• Below 50 years
• Above 50 years

Market, By End-user

• Hospitals
• Ambulatory surgical centers
• Dermatology clinics
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa